Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor

Response to Letter by van Werkum: Proton pump inhibitors and clopidogrel: a difficult dilemma

(2009) Jolanta M. Siller-Matula et al.   AMERICAN HEART JOURNAL

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

(2009) D. N. Juurlink et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome

(2009) P. Michael Ho   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2008) Stephen D. Wiviott et al.   CIRCULATION

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

(2008) David S. Small et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2

(2008) E. T. Williams et al.   DRUG METABOLISM AND DISPOSITION

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

(2008) David S. Small et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin

(2008) Martine Gilard et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

(2008) Nagy A Farid et al.   PHARMACOTHERAPY

The active metabolite of prasugrel effectively blocks the platelet P2Y12receptor and inhibits procoagulant and pro-inflammatory platelet responses

(2008) Heather M. Judge et al.   PLATELETS

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species

(2007) Yoichi Niitsu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

(2007) Nag A. Farid et al.   JOURNAL OF CLINICAL PHARMACOLOGY